Abstract
e13581 Background: UGT1A1 plays a major role in the glucuronidation of the histone deacetylase inhibitor belinostat (BEL). Polymorphisms with reduced UGT1A1 function could result in increased BEL exposure, global protein lysine acetylation (AcK) and toxicities (tox). Methods: In a Phase I (BPE) and Phase I/II trial (BPAC), BEL (400-1000 mg/m2/24 h) was administered by 48 h continuous infusion in combination with either cisplatin (P) and etoposide (E), or P, doxorubicin (A) and cyclophosphamide (C), respectively. Pts with small cell lung cancer and other cancers of neuroendocrine origin (n = 25 in BPE) or thymic epithelial tumors (n = 26 in BPAC) were genotyped for UGT1A1 variants associated with reduced function: UGT1A1*6, UGT1A1*28 and UGT1A1*60. In both trials PK BEL parameters and clinical outcomes were monitored during cycle 1. Endpoints were associations between UGT1A1 genotype and BEL PK, AcK, and tox. Results: Carriers of UGT1A1*60 variants in BPE, had progressively higher BEL t1/2 than WTs: P= 0.0...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
